This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Greetings and welcome to the Capricorn Therapeutics third quarter 2021 earnings call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. A.J. Bergman, Chief Financial Officer. Please go ahead, sir.
spk04: Thank you. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our product candidates, our future R&D plans, including our anticipated conduct and timing of preclinical and clinical studies, our plans to present or report additional data, our plans regarding regulatory filing, potential regulatory developments involving our product candidates, and our possible uses of existing cash and investment resources. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports. We are cautioned not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements. With that, I will turn the call over to Linda Marban, CEO.
spk02: Thank you, AJ. Good afternoon, and thank you for joining us for our third quarter conference call. Today, I will be providing updates on our two pipeline programs, first CAP-1002, which is our allogeneic cell therapy currently in late-stage clinical development to treat Duchenne muscular dystrophy and severe COVID-19. I will also provide an update on our emerging platform technology, involving exosomes as drug delivery vehicles. First, I will discuss CAP-1002 and DMG. In late September, we presented our final data from the HOPE II Phase II clinical trial at a late-breaking session of the World Muscle Society. The data conclusively showed that the trial hit its primary efficacy endpoint of the performance of the upper limb, or PULL, mid-level 1.2, and more importantly, suggested clinical relevance with a difference in decline of 2.6 points between treated and placebo patients. To remind you, FDA has said that a one-point change would be considered clinically relevant. Patients in HOPE II were largely non-ambulant and in the later stage of the disease process, for which very few therapeutic options exist. Data from the placebo-controlled trials show that these patients that received CAP-1002 had a 71% slowing of the decline of mid-level upper limb function, that means arm function, as measured by the performance of the upper limb, or pull, which suggests a strong impact on functional ability. Additionally, and of great importance, is that we also showed significant improvement in cardiac function as measured by ejection fraction and end systolic index volume, which suggests that treatment with CAP-1002 could slow the decline in the cardiac function associated with the cardiomyopathy of DMT, one of the leading causes of death in patients with Duchenne muscular dystrophy. The data also showed significant improvements in the full pull 2.0, which to remind you is total shoulder, arm, and hand function, and is the updated version of this important test. Importantly, it is also the primary efficacy endpoint of HOPE III, our planned Phase III pivotal trial. I'm also pleased to share with you today that the FDA has cleared HOPE III to proceed. We will be aiming to enroll approximately 70 patients in the randomized, double-blind, placebo-controlled study across approximately 20 sites in the United States. At this time, we have initiated site selection and initial startup activities for this study. As you know, we have secured important regulatory designations, including RMAT, or the Regenerative Medicine Advanced Therapy designation, and we qualify for a rare pediatric coupon voucher upon product approval. We remain committed to continue to work with FDA in our efforts to bring this important therapeutic to patients as quickly as possible. In addition, the open-label extension portion of HOPE II is underway, with 12 patients having already received at least four doses. We are collecting safety data from these patients and following some of them using an optional DVA or Duchenne video assessment tool, which evaluates patients in their home settings and allows tracking of disease progression or attenuation using activities of daily living. We presented some of this data at the parent project for muscular dystrophy meeting in late June 2021. The most notable aspect of that presentation was a video of a young man named Carter sitting up in bed prior to being treated with TAP-1002, and another video of him attempting the same task 10 weeks after being treated with TAP-1002. This particular task has been highlighted by patients as having one of great impact on one's quality of life. Here, a picture paints a thousand words, and I highly recommend that you visit our website to see this video. Additionally, many of the families whose sons are receiving CAP1002 are reporting delays in disease progression and even improvements in function. We are hopeful, along with those families, that CAP1002 can improve the trajectory of DMD. Finally, I would like to highlight several important facts regarding the use of CAP1002 for the treatment of DMD, focusing first on the current dosing regimen and why we think HOPE II shows such positive clinical findings, and also where CAP-10-02 fits in the therapeutic arena to treat DMD. Our first clinical trial in DMD, HOPE-2-SHEM, was designed as a single-dose, 75-million-cell study with a one-year follow-up. Cells were delivered directly to the heart via intracoronary catheterizations. Patients were those with significant cardiac scar and were largely non-ambulant. The data showed the greatest improvements in upper limb skeletal muscle strength as measured by the performance of the upper limb 1.2 mid plus distal or arm and hand function in the first three months. This observation led to a change in our dosing frequency. We needed to dose every three months. This could be more easily accomplished using intravenous or IV dosing rather than intracoronary delivery. Therefore, based on extensive non-clinical studies, we were able to move to an IV delivery method and increase the dose to 150 million cells every three months. HOPE II and HOPE II open-label extension are the first clinical efforts in which patients received the calculated maximal effective dose of 150 million cells four times a year or once every three months. And the data shows sustained improvement in upper limb function as well as significant improvements in cardiac function, as we recently showed at World Muscle Society. Secondly, we also believe that CAP10 or 2 can be used along with any other treatments for DMD. Its mechanism of action is to reduce the inflammation and corresponding fibrosis caused by DMD, as well as drive muscle stem cells to build healthy new muscles. This is necessary to combat DMD even if it is in the setting of possible gene therapies which are currently under investigation for DMD. We are committed to getting CAB 1002 for DMD to patients as quickly as possible. And based on the strength of the data, we are evaluating the best way to move this program forward most expeditiously towards registration. We will provide updates on this program as they become available. I would also like to take a moment here to thank the patients and their families for not only participating in our clinical trials, but also for their support in driving CAP 1002 forward to treat DMD. Every email and text message that I receive from families who want CAP 1002 for their sons reminds me of the importance of our mission and the potential opportunity for CAP 1002 to treat DMD. I will now provide you with an update on INSPIRE. our clinical trial using a single dose of CAP-10 or 2 to treat severe COVID-19 patients. This is a trial that was designed to enroll approximately 60 patients with severe but not critical COVID-19, which means that they are having trouble breathing but are not yet requiring ventilation. The trial was designed based on our treatment of a series of patients relatively early in the pandemic, which was published in the peer-reviewed journal basic research in cardiology, and showed the potential benefit of CAP10O2 in patients who are not already on ventilators. These are the patients we targeted in INSPIRE. I am delighted to share today that enrollment in that trial is complete. The trial had a 90-day primary safety endpoint as mandated by FDA, and based on that timeline, we plan to release top-line data in the first quarter of 2022. In conjunction with the United States Army Institute of Surgical Research, we recently published data which showed that the exosomes released by CAP-1002 had beneficial effects in trauma and the hyper-inflammatory consequences of such, which is similar to the pathogenesis of severe COVID-19. Based on that data and the published mechanism of action of CAP-1002, we believe that CAP-1002 could be an important tool in treating those patients with respiratory compromise, but who are not yet in need of ventilatory support. While a lot of progress has been made in treating COVID, there are still very few options for this particular group of patients. We will provide updates on this important program as they become available. Now, I would like to move on and spend a few minutes providing an update on our Exosome platform technology. As we have been discussing for a while, We believe that exosomes may have an important future in biotechnology and should become a cornerstone in delivering payloads inside or across the cell membrane, whether it's a nucleic acid, such as RNA, proteins, or even synthetic small molecules. Exosomes are nature's delivery system. They are non-toxic, non-immunogenic, and can be targeted to specific cell types by taking advantage of the receptors on their surface that allow them to bind directly to a cell and deliver contents safely inside. For several decades, science has been wrestling with the concept that protein transcription and translation could be modified to address many diseases if RNA could get inside the cell and turned into protein. To that end, the development of lipid nanoparticles to facilitate transmission as well as to protect the RNA from degradation has made the concept of RNA medicines possible. However, these lipids are not without significant problems which potentially may be solved by exosomes. In order to develop a platform using exosomes to deliver RNA and also demonstrate high fidelity protein translation, we decided to develop a vaccine which would be an efficient tool to assess loading and protein expression. We chose COVID-19 as our first target for a couple of reasons. The first, of course, is because of its societal relevance. The second is that we believe that a unique vaccine, which is multivalent or has more than one of the major viral proteins included, as well as the fact that the mRNA would be delivered via exosomes, could potentially confer stronger, and longer-lasting immunity. The data from the non-clinical studies of this vaccine candidate has recently been published in the Journal of Biological Chemistry and is being developed as either a de novo vaccine or a booster to support those vaccines that are already approved. As we previously stated, we have shown that exosomes are less toxic than the LNPs or lipid nanoparticles used to deliver the currently approved vaccine, and therefore may be a good vehicle for other vaccines as well. It is uncertain, but it is possible that many of the adverse effects of the lipid nanoparticle mRNA vaccines, most importantly myocarditis, may be mediated by the lipid nanoparticle delivery system, which leaves open the opportunity for safer delivery vehicles in vaccinology moving forward. We believe that the exosomes might be safer as well as effective. In fact, we have recent data that shows inflammation in the hearts of animals injected with a lipid nanoparticle plus RNA. The inflammation is not present in the exact same exosome-based formulation with exactly the same RNA constructs, suggesting less toxicity in the exosome population. RNA formulation. Our objective with our vaccine program is to establish the proof of concept of our exosome platform for the larger vaccine industry. We believe that many vaccines of the future, whether they be for infectious diseases or cancer, will use RNA as a substrate for antigen presentation to the immune system. We had specific pre-IND feedback from FDA on our vaccine candidates, and we are now completing those studies necessary for an ING. All of the data we have collected and the responses of the FDA support the future development of our platform model loading exosomes, whether for therapeutic development or other vaccines. Important to these development efforts, we have now relocated our R&D headquarters to San Diego, California. and have assembled a strong team of scientists with expertise in exosomes and RNA loading. This team is working in a strategic manner to build and expand Capricor's platform in 2022 and 2023. As we have been messaging since we introduced the concept of an engineered exosome platform, some of what we develop we will keep in-house for clinical development, and others we will aim to potentially license out to partners that desire exosome-based drug delivery. As our platform matures, we believe this is the most strategic way to monetize this opportunity. We believe that the groundwork we are laying will facilitate future development of our exosome platform, and this is even more relevant in the current setting where RNA delivery is coming to the forefront in biotechnology. And we believe our engineered exosome platform technology will enable Capricor to become a leader in the space. In closing, I want to thank you for your support. We look forward to providing continuing updates on all of our programs. Again, thank you. I will now turn the call over to A.J. Bergman, our CFO, for an update on the financials.
spk04: Thank you, Linda. This afternoon's press release provided a summary of our third quarter of 2021 financials on a GAAP basis. You may also refer to our quarterly report on Form 10Q, which we expect to become available in the next few days and will be accessible on the SEC website as well as in the financial section of the company website. As of September 30, 2021, the company's cash and cash equivalents totaled approximately $40.8 million compared to approximately $32.7 million on December 31, 2020. Based on our current pipeline and operating plans, the company's cash position is expected to be sufficient to support operations for at least two years. Turning now to the financials. Over the first nine months of 2021, our net cash used in operating activities was approximately $11.2 million. For the third quarter of 2021, excluding stock-based compensation, our research and development expense was approximately $2.4 million compared to approximately $2.6 million in Q3 2020. Again, excluding stock-based compensation, our general and administrative expense was approximately $1.1 million in Q3 2021 and approximately $900,000 in Q3 2020. Net loss for the first nine months of 2021 was approximately $13.8 million compared to a net loss of approximately $9.5 million for the first nine months of 2020. We will now open the lineup for questions. Operator, will you please open the line up for questions?
spk01: Thank you. We'll now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for your questions. Our first question comes from the line of Joe Pangenis with HC Wainwright. Please proceed with your question.
spk03: Hi, Linda and AJ. Good afternoon. Thanks for taking the question. A few questions, if you don't mind. Let's start with HOPE III. Obviously, the path forward for this study is iterative, lots of FDA feedback and discussions that you've had. You know, previously you've discussed maybe not moving forward with this study unless it's in the hands of a partner. You know, today you're talking about evaluating potential options. So I guess I'll ask the question this way. Is this something that you could potentially now bring forward yourself based on the FDA feedback and the cash runway that you delineated today?
spk02: Hi, Joe. It's always a pleasure to hear from you. Thank you so much. So we are incredibly encouraged by the data from HOPE II. And we are now developing the plan to get HOPES restarted. We're working on initiating the site, getting startup activities going, and we are poised to enroll patients. So we hope you and others will stay tuned to how we decide to do that.
spk03: Understood. Okay. And I guess, you know, however it moves forward, I guess can you talk about the manufacturing readiness to be able to deliver products for the study program? and anything that's still outstanding? And when you look at the macro environment right now from a manufacturing standpoint or any of your ongoing operations, are there any impacts from the global supply chain issues?
spk02: Yeah, thanks for that. I know we're very lucky that we had planned on manufacturing for Hope 3 a while ago. So in terms of supply chain, we're in very good shape. We're in good shape to begin the study immediately, and there will be no issues regarding product. In terms of the commercial development of the cells, we are working and continue to plan and working closely with FDA through HOPE III and into the BLA period so that we are ready with commercial supply when the drug is launched. And so this is an area of active activity for our team at this time.
spk03: Got it, got it. And then it's definitely nice to see a full enrollment of INSPIRE today. A little forward-looking, obviously, Pending positive data, is there anything that you can, you know, maybe describe as potential next steps?
spk02: Yeah, so obviously the data tells the story, so we'll be excited to look at the data ourselves and, of course, share it. And based on what the data shows us, we will evaluate next steps and keep everyone updated as to that plan.
spk03: Got it, got it. And then, you know, I'm certainly intrigued always, you know, with the exosomes platform, you know, platform that you have here and the BD potential around that. So I guess, of course, this depends on, you know, what cash spend that you have or don't have around HOPE III. But since you have two years of cash right now, it seems like you'd be able to deliver a lot of both preclinical and potentially early clinical data over the next two years. Is there some sort of framework that you can provide as to the level of visibility that the exosomes platform could deliver?
spk02: Yeah, so we have been planning carefully to give the exosomes a good runway. We have several targets that are in development, including the vaccine that I spoke about today regarding for COVID and also for future vaccine development. There are other programs that are in preclinical assessment as we speak, and we look forward to providing updates to that as it becomes available. Now, I will add here that the exosomes are now the platform upon which we are building the delivery of biologics. This can be nucleic acids such as RNA, which are our first targets, could be proteins, could be small molecules. Exosome display is also a possibility where you can coat the exosome on the outside with a protein and drive either other types of vaccines or potentially protein replacement therapy. Their opportunities are large. What we've been able to do is narrow it down to a few specific targets that we are actively engaged in, and we'll provide updates on that really in the first part of next year.
spk03: Thank you, Linda.
spk02: Thanks, Joe.
spk01: Thank you. Once again, as a reminder, if you would like to ask a question, please press star 1 on your telephone keypad. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for more questions. There are no further questions at this time. I'd like to turn the call back over to Ms. Linda Marban for closing remarks.
spk02: Thank you very much for joining us for our third quarter updates. We look forward to providing updates as they become available on our pipeline programs, CAP 1002 and the exosomes, and thank you for your time today.
spk01: Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation and have a wonderful day.
Disclaimer